Lancet Psychiatry:大麻二酚用于大麻使用障碍的治疗

2020-08-01 MedSci原创 MedSci原创

400毫克和800毫克大麻二酚具有治疗大麻使用障碍的效果,其效果优于安慰剂

目前临床上仍缺少治疗大麻使用障碍的有效药物手段。近日研究人员开展IIa期研究考察了大麻二醇对大麻使用障碍的治疗效果。
 
研究人员在英国进行了本次IIa期、双盲、安慰剂对照、随机、适应性贝叶斯试验,以确定大麻二醇治疗大麻使用障碍的有效剂量。在试验的第一阶段,符合DSM-5大麻使用障碍标准的参与者随机接受三种不同剂量的大麻二醇(200 mg、400 mg或800 mg)或安慰剂,持续4周。所有参与者都接受了简短的心理干预。在试验的第二阶段,新的参与者随机接受安慰剂或在中期分析中被认为有效的大麻二醇剂量。研究的主要目的是可减少患者大麻使用的最有效的大麻二醇剂量。有效性的评估手段为尿液中11-nor-9-羧酸-δ-9-四氢大麻酚(THC-COOH)/肌酐,治疗期间大麻戒除每周增加天数。
 
研究的第一阶段,48名参与者随机接受安慰剂(n=12)、200 mg(n=12)、400 mg(n=12)和800 mg(n=12)的大麻二醇。在中期分析中,200mg大麻二醇作为无效剂量被排除。在第二阶段,另外34名参与者随机给予400mg的大麻二醇(n=12)、800mg的大麻二醇(n=11)和安慰剂(n=11)。在最终分析中,400 mg和800 mg大麻二醇组达到了主要终点,与安慰剂相比,400mg大麻二醇和800mg大麻二醇成为最有效剂量的概率为0.9995和0.9965。在戒除大麻的期间,与安慰剂相比,400mg大麻二醇和800mg大麻二醇成为最有效剂量的概率为0.9966和0.9247。与安慰剂相比,400mg大麻二醇酚使THC-COOH:肌酐减少94.21 ng/mL,每周大麻戒除时间增加了0.48天。与安慰剂相比,800mg大麻二醇可使THC-COOH:肌酐减少72.02 ng/mL,每周戒除大麻的时间增加0.27天。大麻二醇耐受性良好,无严重不良事件记录,82名参与者中77名(94%)完成了治疗。
 
研究认为,400毫克和800毫克大麻二酚具有治疗大麻使用障碍的效果,其效果优于安慰剂。
 
原始出处:
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830765, encodeId=2df71830e653c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Sep 18 07:28:32 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891674, encodeId=6ae98916e4e8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Oct 13 08:04:11 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792180, encodeId=43001e92180a7, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Sep 27 21:28:32 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813689, encodeId=757581368969, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:52:17 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272760, encodeId=3cc312e276067, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368592, encodeId=bc661368592a0, content=<a href='/topic/show?id=7732440614d' target=_blank style='color:#2F92EE;'>#大麻二酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44061, encryptionId=7732440614d, topicName=大麻二酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033909, encodeId=3018103390902, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 01 13:28:32 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830765, encodeId=2df71830e653c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Sep 18 07:28:32 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891674, encodeId=6ae98916e4e8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Oct 13 08:04:11 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792180, encodeId=43001e92180a7, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Sep 27 21:28:32 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813689, encodeId=757581368969, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:52:17 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272760, encodeId=3cc312e276067, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368592, encodeId=bc661368592a0, content=<a href='/topic/show?id=7732440614d' target=_blank style='color:#2F92EE;'>#大麻二酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44061, encryptionId=7732440614d, topicName=大麻二酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033909, encodeId=3018103390902, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 01 13:28:32 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-10-13 14818eb4m67暂无昵称

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1830765, encodeId=2df71830e653c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Sep 18 07:28:32 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891674, encodeId=6ae98916e4e8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Oct 13 08:04:11 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792180, encodeId=43001e92180a7, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Sep 27 21:28:32 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813689, encodeId=757581368969, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:52:17 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272760, encodeId=3cc312e276067, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368592, encodeId=bc661368592a0, content=<a href='/topic/show?id=7732440614d' target=_blank style='color:#2F92EE;'>#大麻二酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44061, encryptionId=7732440614d, topicName=大麻二酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033909, encodeId=3018103390902, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 01 13:28:32 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830765, encodeId=2df71830e653c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Sep 18 07:28:32 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891674, encodeId=6ae98916e4e8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Oct 13 08:04:11 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792180, encodeId=43001e92180a7, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Sep 27 21:28:32 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813689, encodeId=757581368969, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:52:17 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272760, encodeId=3cc312e276067, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368592, encodeId=bc661368592a0, content=<a href='/topic/show?id=7732440614d' target=_blank style='color:#2F92EE;'>#大麻二酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44061, encryptionId=7732440614d, topicName=大麻二酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033909, encodeId=3018103390902, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 01 13:28:32 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1830765, encodeId=2df71830e653c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Sep 18 07:28:32 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891674, encodeId=6ae98916e4e8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Oct 13 08:04:11 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792180, encodeId=43001e92180a7, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Sep 27 21:28:32 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813689, encodeId=757581368969, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:52:17 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272760, encodeId=3cc312e276067, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368592, encodeId=bc661368592a0, content=<a href='/topic/show?id=7732440614d' target=_blank style='color:#2F92EE;'>#大麻二酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44061, encryptionId=7732440614d, topicName=大麻二酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033909, encodeId=3018103390902, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 01 13:28:32 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-03 kcb069
  6. [GetPortalCommentsPageByObjectIdResponse(id=1830765, encodeId=2df71830e653c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Sep 18 07:28:32 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891674, encodeId=6ae98916e4e8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Oct 13 08:04:11 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792180, encodeId=43001e92180a7, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Sep 27 21:28:32 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813689, encodeId=757581368969, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:52:17 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272760, encodeId=3cc312e276067, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368592, encodeId=bc661368592a0, content=<a href='/topic/show?id=7732440614d' target=_blank style='color:#2F92EE;'>#大麻二酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44061, encryptionId=7732440614d, topicName=大麻二酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033909, encodeId=3018103390902, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 01 13:28:32 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1830765, encodeId=2df71830e653c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Sep 18 07:28:32 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891674, encodeId=6ae98916e4e8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Oct 13 08:04:11 CST 2020, time=2020-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792180, encodeId=43001e92180a7, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sun Sep 27 21:28:32 CST 2020, time=2020-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813689, encodeId=757581368969, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 07:52:17 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272760, encodeId=3cc312e276067, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368592, encodeId=bc661368592a0, content=<a href='/topic/show?id=7732440614d' target=_blank style='color:#2F92EE;'>#大麻二酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44061, encryptionId=7732440614d, topicName=大麻二酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Mon Aug 03 01:28:32 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033909, encodeId=3018103390902, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Aug 01 13:28:32 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-01 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

相关资讯

Lancet Psychiatry:大麻使用与后继精神疾病风险

研究认为,使用频率和高效能大麻导致精神障碍发病率显著增加,高效能大麻供应的日益增加是公共卫生的严重威胁

Diabetes Care:1型糖尿病成年人大麻的使用与糖尿病酮症酸中毒风险增加有关

由此可见,1型糖尿病成年人使用大麻与DKA风险增加相关。提供者应告知其患者使用大麻可能引起DKA的潜在风险。

GW的大麻类药物Epidyolex获得欧盟批准治疗儿童癫痫

GW Pharma的大麻类Epidyolex药物获得了里程碑式的批准,欧洲监管机构已将其批准用于治疗两种罕见的严重儿童期癫痫病患者的癫痫发作。Epidyolex是大麻二酚的口服溶液,源自大麻植物。

Clin Chem:控制大麻吸入后Δ9-Tetrahydrocannabinol浓度和释放动力学的相关性

众所周知,使用大麻会影响驾驶,并增加车祸的风险。大麻素在血液和其他基质中的浓度在使用后很长一段时间内都保持在较高水平,这就对急性和慢性接触的区分非常困难。呼气被认为是一种替代基质,其中浓度可能更接近于损伤窗口;然而,有效的捕获和分析灵敏的检测方法仍需要进一步评估。 · 2019-10-19

-->

JAMA Network Open:大麻能够减轻镰状细胞病疼痛

加州大学欧文分校研究员Kalpna Gupta和加州大学旧金山分校的Donald Abrams博士共同领导的一项临床试验表明,大麻似乎是治疗镰状细胞疾病慢性疼痛的一种有效疗法。

大麻制剂:预防器官移植引起的缺血和再灌注损伤

Revive Therapeutics是一家针对罕见炎症性疾病开发新型大麻素疗法的生命科学公司。